Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Murphy Analytics releases report on Bohai Pharmaceuticals

Bohai Pharmaceuticals Group, Inc., a China-based pharmaceutical company engaged in the production, manufacturing and distribution of Traditional Chinese Medicine (TCM) in China, today announced the release of an in-depth initiation report by Patrick Murphy, CFA, principal of fee-based independent research firm Murphy Analytics.

18 Sep 2010

Ligand Pharmaceuticals transfers license rights to Proximagen for CXCR4 target

Ligand Pharmaceuticals Incorporated announced today that it has transferred exclusive license rights to Proximagen Limited for a series of compound hits related to the CXCR4 target with application for a number of indications including those related to the central nervous system. Ligand will receive an upfront payment and continue to be entitled to receive potential future milestone and royalty payments.

18 Sep 2010

Conference to discuss frontline of immunological research, its clinical application

The immune system is evolved to protect our body against a variety of infectious agents which can cause serious and often fatal diseases. We now appreciate that the immune system is also involved in surveillance of malignant transformation of normal cells that constitute our body, as well as rejection of transplanted organs.

17 Sep 2010

SBi reports continuing growth for S.T.A.R. ankle arthroplasty implant system

Small Bone Innovations, Inc. (SBi), a leading, privately held orthopedics company focused primarily on arthroplasty and trauma reconstruction technology and treatments for the small bones & joints, reported continuing growth for its S.T.A.R. ankle arthroplasty implant system with August being the biggest month ever for the S.T.A.R. in terms of revenues and surgeries.

From Evident Corporation - Life Sciences 17 Sep 2010

Prometheus, Tarrot announce exclusive agreement for Crohn's Disease treatment

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, and Tarrot Laboratories, a business unit of Cedars-Sinai Medical Center, today announced the execution of an exclusive research collaboration and license agreement. The collaboration will focus on identifying genetic or serologic markers associated with clinical responses to anti-TNF therapies such as Cimzia, Humira and Remicade utilized in the treatment of Crohn's Disease, and the subsequent development of diagnostic tests.

17 Sep 2010

Study identifies venous thromboembolism risk factors after THR surgery

Risk factors for venous thromboembolism after total hip replacement (THR) surgery were identified in a new study published in the September 2010 issue of The Journal of Bone and Joint Surgery (JBJS). While the rate of thromboembolism has been significantly reduced through medication, understanding the risk factors could further reduce the likelihood of patients developing this potentially fatal complication.

17 Sep 2010

Scientists discover new drug target to improve radiation effectiveness for treating cancer

Scientists at Washington University School of Medicine in St. Louis have discovered a new drug target that could improve the effectiveness of radiation for hard-to-treat cancers.

17 Sep 2010

ISTA Pharmaceuticals initiates REMURA Phase 3 clinical program for dry eye disease

ISTA Pharmaceuticals, Inc., today announced that it has initiated a Phase 3 clinical program of ISTA's proprietary formulation of REMURA (bromfenac ophthalmic solution for dry eye) for alleviating the signs and symptoms of dry eye disease. The Phase 3 efficacy studies are being conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. Food and Drug Administration (FDA).

16 Sep 2010

BioCryst Pharmaceuticals announces BCX4208 compound results for treating gout

BioCryst Pharmaceuticals, Inc. announced positive top-line results from its randomized, double-blind, multi-center, placebo-controlled Phase 2 study designed to evaluate the urate-lowering activity and safety of several doses of BCX4208 alone and in combination with selected doses of allopurinol administered once-daily.

16 Sep 2010

Endoscopic laser spine procedures replace traditional open back surgery

The Bonati Spine Institute, the leading center for the patented Bonati Spine Procedures for minimally invasive laser spine surgery, supports recent studies by highly respected organizations such as the Journal of the America Board of Family Medicine and Consumer Reports reporting an unnecessary growth in tests and treatments targeting back pain.

16 Sep 2010

Researchers to conduct gene analysis for ankylosing spondylitis

A new study designed to test suspected links between genes and two immune disorders could open the door to better ways to diagnose and treat the conditions that affect a combined total of approximately 2.5 million people in the United States, report scientists at The University of Texas Health Science Center at Houston (UTHealth).

16 Sep 2010

GSK, Genmab to refocus on ofatumumab development program in autoimmune indications

GlaxoSmithKline and Genmab A/S Following the 1st July announcement by GSK and Genmab of an amendment to the collaborative agreement for ofatumumab in which GSK assumed development responsibility for autoimmune indications, GSK and Genmab announced today plans to refocus the development program of ofatumumab in autoimmune indications.

16 Sep 2010

HHS awards grant to develop patient-centered outcomes research

U.S. Department of Health and Human Services (HHS) Assistant Secretary for Health, Howard K. Koh, MD, MPH, today announced the award of more than $14 million to develop, implement, and test strategies to increase the adoption and dissemination of interventions based on patient-centered outcomes research among racial and ethnic minority populations.

16 Sep 2010

Bohai adds additional pharmaceutical products to Traditional Chinese Medicine portfolio

Bohai Pharmaceuticals Group, Inc., a China-based pharmaceutical company engaged in the production, manufacturing and distribution of Traditional Chinese Medicine (TCM) in China, today announced the introduction of five additional pharmaceutical products to its portfolio of TCM offerings.

15 Sep 2010

FDA-cleared LaserTouchOne device for chronic and acute pain treatment available without prescription

The American Pain Foundation reports that despite the fact that the majority of the U.S. population looks healthy, statistics tell a different story: Approximately 1 in 3 Americans suffer from chronic pain. This chronic pain could be related to an illness like cancer or rheumatoid arthritis, or a condition such as arthritis, migraine headaches, fibromyalgia or back pain from a car accident.

15 Sep 2010

Broccoli blocks joint destruction in osteoarthritis: Research

Scientists at the University of East Anglia (UEA) are launching a groundbreaking new project to investigate the benefits of broccoli in the fight against osteoarthritis.Initial laboratory research at UEA has found that a compound in broccoli called sulforaphane blocks the enzymes that cause joint destruction in osteoarthritis the most common form of arthritis.

15 Sep 2010

Researchers identify risk gene for schizophrenia

An international team of researchers has identified a risk gene for schizophrenia, including a potentially causative mutation, using genome-wide association data-mining techniques and independent replications.

15 Sep 2010

FDA approves Krystexxa drug to treat gout

The U.S. Food and Drug Administration approved Krystexxa (pegloticase) to treat the painful condition known as gout in adults who do not respond to or who cannot tolerate conventional therapy.

15 Sep 2010

Apricus Biosciences announces reformulation of Rituxan enables rectal delivery of biologics

Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT drug delivery technology and internal pipeline through out-licensing arrangements and partnerships, today announced results from a pre-clinical pharmacokinetic study showing the ability of NexACT to enable rectal delivery of biologics, such as human antibodies.

15 Sep 2010

VBL Therapeutics' VB-201 candidate delays onset of EAE, shows potential for MS, CNS treatment

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the publication of preclinical data in the Journal of Neuroimmunology finding that its lead development candidate VB-201 significantly delayed the onset and severity of experimental autoimmune encephalomyelitis (EAE) in mice, the commonly used Multiple sclerosis.

14 Sep 2010

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Murphy Analytics releases report on Bohai Pharmaceuticals

Ligand Pharmaceuticals transfers license rights to Proximagen for CXCR4 target

Conference to discuss frontline of immunological research, its clinical application

SBi reports continuing growth for S.T.A.R. ankle arthroplasty implant system

Prometheus, Tarrot announce exclusive agreement for Crohn's Disease treatment

Study identifies venous thromboembolism risk factors after THR surgery

Scientists discover new drug target to improve radiation effectiveness for treating cancer

ISTA Pharmaceuticals initiates REMURA Phase 3 clinical program for dry eye disease

BioCryst Pharmaceuticals announces BCX4208 compound results for treating gout

Endoscopic laser spine procedures replace traditional open back surgery

Researchers to conduct gene analysis for ankylosing spondylitis

GSK, Genmab to refocus on ofatumumab development program in autoimmune indications

HHS awards grant to develop patient-centered outcomes research

Bohai adds additional pharmaceutical products to Traditional Chinese Medicine portfolio

FDA-cleared LaserTouchOne device for chronic and acute pain treatment available without prescription

Broccoli blocks joint destruction in osteoarthritis: Research

Researchers identify risk gene for schizophrenia

FDA approves Krystexxa drug to treat gout

Apricus Biosciences announces reformulation of Rituxan enables rectal delivery of biologics

VBL Therapeutics' VB-201 candidate delays onset of EAE, shows potential for MS, CNS treatment

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in